Natera FY2024 preliminary revenue ~$1.7B (+56% YoY), positive cash inflow $86.3M

Natera, Inc.

2024-FY EPS reported -$1.53 revenue$1,696,911,000

Q4 2024 revenue ~$472M (+52% YoY); FY2024 revenue ~$1.7B (+56% YoY), ~$53M above top end of guidance.
Positive non-GAAP cash inflow of $86.3M in FY2024 vs. outflow of $267.1M in FY2023.
Total tests processed in FY2024 ~3.06M (+22.8% YoY); Q4 oncology tests up 54.7% to ~150,800.
Clinical oncology tests in FY2024 ~498,300 (+63% YoY); Q4 sequential increase of ~14,800 tests.
Company to present additional updates at J.P. Morgan Healthcare Conference on Jan 15, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.